Michael Sperling AES, 2021: Diazepam Nasal Spray in Patients with Seizure Clusters – Subgroup Analysis from a Phase 3 Safety Study
touchNEUROLOGY met with Prof. Michael Sperling (Thomas Jefferson University, Philadelphia, PA, USA) to discuss a subgroup analysis from a phase 3 safety study investigating the use of diazepam nasal spray in patients with seizure clusters concomitantly receiving clobazam. Diazepam nasal spray is an FDA-approved nasal spray version of diazepam, indicated for the treatment of acute, intermittent, and stereotypic episodes of frequent seizure activity in epilepsy patients six years of age and older.
The abstract entitled: ‘Evaluation of Diazepam Nasal Spray in Patients with Seizure Clusters Concomitantly Receiving Clobazam: A Subgroup Analysis from a Completed Phase 3, Long-Term, Open-Label Safety Study’, was presented at the American Epilepsy Society (AES) Annual Meeting, 3-7 December 2021.
- How common is the concomitant use of diazepam nasal spray and benzodiazepines in the treatment of seizure clusters in patients with epilepsy?
- Could you give us a brief overview of the long-term safety study evaluating the eﬀectiveness and safety of diazepam nasal spray?
- What were the aims and design of the current subanalysis?
- What did the findings teach us about the impact of concomitant benzodiazepines on the effectiveness and safety profile of diazepam nasal spray?
- What is the clinical significance of this study?
Disclosures: Michael Sperling has received compensation for speaking at CME programs from Medscape, Projects for Knowledge, International Medical Press, Eisai, and UCB Pharma. He is an advisor for scientific publications for Neurelis. He consults for Medtronic and J & J. He has received research support from Eisai; Medtronic; Neurelis; SK Life Science; Takeda; Xenon; Cerevel; UCB Pharma; and Engage Pharmaceuticals. He has received royalties from Oxford University Press and Cambridge University Press.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Filmed as a highlight of AES, 2021
Share this Video
Related Videos In Epilepsy
Jacqueline French, AAN 2023: XEN1101, a novel potassium channel modulator for the treatment of focal epilepsy
In this interview with touchNEUROLOGY, Prof. Jacqueline French (Comprehensive Epilepsy Center, New York University, New York, NY, US) discusses the needs of adults with focal epilepsy and the mechanisms of action of XEN1101, a novel, potent, selective Kv7.2/7.3 potassium channel. The abstract entitled “XEN1101, a Novel Potassium Channel Modulator: Interim Data From an Ongoing, Long-Term, […]
Jacqueline French, AAN 2023: X-TOLE phase 2b open-label extension trial of XEN1101 in focal epilepsy – interim data
The randomized, double-blind, placebo-controlled phase IIb study X-TOLE (NCT03796962) is investigating the efficacy of XEN1101, a novel potassium channel modulator, in adults with focal epilepsy. In this interview with touchNEUROLOGY, Prof. Jacqueline French (Comprehensive Epilepsy Center, New York University, New York, NY, US) discusses this clinical trial and the outcomes of its open-label extension. The […]
Galia Wilson, Dravet Syndrome UK: DSUK Objectives, directions and support for families and people living with Dravet syndrome
Dravet Syndrome (DS) is a rare neurological condition, beginning in infancy and lasting a lifetime. touchNEUROLOGY were joined by Galia Wilson, Chair and Trustee of Dravet Syndrome UK (DSUK), a charity created in 2008 by a group of parents who came together looking for support, resources and information relating to the neurological condition. In this interview, […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!